Korro Bio Inc
KRRO33.840USD
+1.270+3.90%
終値 11/07, 16:00（ET）15分遅れの株価
317.79M時価総額
損失額直近12ヶ月PER
詳細情報 Korro Bio Inc 企業名
Korro Bio, Inc. is a biopharmaceutical company. The Company discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The Company is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Its Oligonucleotide Promoted Editing of RNA (OPERA) is a foundational platform for RNA editing, which is designed to edit RNA in vivo by delivering an oligonucleotide guide that can target specific RNA sequences. The Company’s first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD), that has the potential to be disease-modifying and provide a differentiated therapeutic option.
Korro Bio Incの企業情報
企業コードKRRO
会社名Korro Bio Inc
上場日Oct 03, 2019
最高経営責任者「CEO」Dr. Ram Aiyar, Ph.D.
従業員数104
証券種類Ordinary Share
決算期末Oct 03
本社所在地One Kendall Square. Building 600-700
都市CAMBRIDGE
証券取引所NASDAQ Capital Market Consolidated
国United States of America
郵便番号02139
電話番号16174681999
ウェブサイトhttps://www.korrobio.com/
企業コードKRRO
上場日Oct 03, 2019
最高経営責任者「CEO」Dr. Ram Aiyar, Ph.D.
Korro Bio Incの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Nessan Bermingham, Ph.D.
Dr. Nessan Bermingham, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
35.11K
--
Mr. Jeffrey (Jeff) Cerio, Pharm.D.
Mr. Jeffrey (Jeff) Cerio, Pharm.D.
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
--
--
Mr. Oliver Dolan
Mr. Oliver Dolan
Principal Accounting Officer
Principal Accounting Officer
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
--
--
Mr. Venkat Krishnamurthy, Ph.D.
Mr. Venkat Krishnamurthy, Ph.D.
Senior Vice President - Platform
Senior Vice President - Platform
--
--
Ms. Stephanie Engels
Ms. Stephanie Engels
Senior Vice President - People and Culture
Senior Vice President - People and Culture
--
--
Dr. Rachel Meyers, Ph.D.
Dr. Rachel Meyers, Ph.D.
Independent Director
Independent Director
--
--
Dr. Katharine (Kate) Knobil, M.D.
Dr. Katharine (Kate) Knobil, M.D.
Independent Director
Independent Director
--
--
Mr. Todd Chappell
Mr. Todd Chappell
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Ram Aiyar, Ph.D.
Dr. Ram Aiyar, Ph.D.
President, Chief Executive Office (Principal Executive Officer), Interim Chief Financial Officer and Principal Financial Officer, Director
President, Chief Executive Office (Principal Executive Officer), Interim Chief Financial Officer and Principal Financial Officer, Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Nessan Bermingham, Ph.D.
Dr. Nessan Bermingham, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
35.11K
--
Mr. Jeffrey (Jeff) Cerio, Pharm.D.
Mr. Jeffrey (Jeff) Cerio, Pharm.D.
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
--
--
Mr. Oliver Dolan
Mr. Oliver Dolan
Principal Accounting Officer
Principal Accounting Officer
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
--
--
Mr. Venkat Krishnamurthy, Ph.D.
Mr. Venkat Krishnamurthy, Ph.D.
Senior Vice President - Platform
Senior Vice President - Platform
--
--
Ms. Stephanie Engels
Ms. Stephanie Engels
Senior Vice President - People and Culture
Senior Vice President - People and Culture
--
--
収益内訳
FY2025Q2
FY2025Q1
FY2024
データなし
地域別USD
会社名
収益
比率
United States
1.46M
0.00%
事業別
地域別
データなし
株主
更新時刻: 8 hours ago
更新時刻: 8 hours ago
株主統計
種類
株主統計
株主統計
比率
Atlas Venture
12.11%
New Enterprise Associates (NEA)
11.62%
Fidelity Management & Research Company LLC
6.81%
Driehaus Capital Management, LLC
6.19%
Platanus Investment LLC
5.75%
他の
57.53%
株主統計
株主統計
比率
Atlas Venture
12.11%
New Enterprise Associates (NEA)
11.62%
Fidelity Management & Research Company LLC
6.81%
Driehaus Capital Management, LLC
6.19%
Platanus Investment LLC
5.75%
他の
57.53%
種類
株主統計
比率
Investment Advisor
30.67%
Hedge Fund
27.09%
Venture Capital
23.72%
Investment Advisor/Hedge Fund
13.96%
Corporation
5.75%
Research Firm
1.37%
Individual Investor
0.42%
Private Equity
0.34%
Pension Fund
0.12%
機関投資家保有株
更新時刻: Wed, Oct 1
更新時刻: Wed, Oct 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q3
186
9.14M
97.37%
-1.25M
2025Q2
186
10.38M
110.55%
-200.85K
2025Q1
189
10.53M
112.24%
-76.97K
2024Q4
194
10.26M
109.50%
+485.90K
2024Q3
177
9.16M
98.29%
-245.98K
2024Q2
167
9.06M
97.57%
+507.87K
2024Q1
179
7.52M
93.89%
+737.20K
2023Q4
198
7.18M
91.01%
+1.51M
2023Q3
223
264.10K
35.84%
-47.15K
2023Q2
235
150.53K
21.10%
-156.09K
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Atlas Venture
1.14M
12.11%
--
--
Jun 30, 2025
New Enterprise Associates (NEA)
1.09M
11.62%
--
--
Jun 30, 2025
Fidelity Management & Research Company LLC
639.22K
6.81%
-4.05K
-0.63%
Jun 30, 2025
Driehaus Capital Management, LLC
580.86K
6.19%
-1.59K
-0.27%
Jun 30, 2025
Platanus Investment LLC
540.16K
5.75%
--
--
Apr 15, 2025
Point72 Asset Management, L.P.
540.07K
5.75%
+19.18K
+3.68%
Jun 30, 2025
Cormorant Asset Management, LP
465.00K
4.95%
+84.70K
+22.27%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
423.16K
4.51%
+15.35K
+3.76%
Jun 30, 2025
Invus Public Equities Advisors, LLC
418.83K
4.46%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
386.74K
4.12%
+4.94K
+1.29%
Jun 30, 2025
詳細を見る
関連ETF
更新時刻: Sun, Nov 2
更新時刻: Sun, Nov 2
銘柄名
比率
iShares Micro-Cap ETF
0.07%
Avantis US Small Cap Equity ETF
0.02%
iShares Russell 2000 Value ETF
0.02%
ProShares UltraPro Russell2000
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 ETF
0.01%
Global X Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
SPDR Portfolio MSCI Global Stock Market ETF
0%
Invesco Dorsey Wright SmallCap Momentum ETF
0%
詳細を見る
iShares Micro-Cap ETF
比率0.07%
Avantis US Small Cap Equity ETF
比率0.02%
iShares Russell 2000 Value ETF
比率0.02%
ProShares UltraPro Russell2000
比率0.01%
ProShares Hedge Replication ETF
比率0.01%
iShares Russell 2000 ETF
比率0.01%
Global X Russell 2000 ETF
比率0.01%
Proshares Ultra Russell 2000
比率0.01%
SPDR Portfolio MSCI Global Stock Market ETF
比率0%
Invesco Dorsey Wright SmallCap Momentum ETF
比率0%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
日付
種類
比率
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
